Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that's good news for Club holding Eli Lilly (LLY).

from Health and Science https://ift.tt/zf3A4Xm
https://ift.tt/ZbEtiMY
https://ift.tt/nLk6SZX